Emyria Limited (EMD.AX)

0.0300 0.0000 (0.00%) At close: 03:06PM AEDT

Emyria Limited

D2, 661 Newcastle Street
Leederville, WA 6007
Australia
61 8 6559 2800
https://emyria.com

Sector(s): Healthcare
Industry: Health Information Services
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michael Winlo	MD & Director	427.95k	N/A	N/A
Dr. Alistair Vickery	Executive Medical Director & Director	485.37k	N/A	N/A
Mr. Joseph Daniel Ohayon ACA, MBA Intl Bus.	Chief Financial Officer	N/A	N/A	N/A
Ms. Tracie Ernenwein	Head of Research & Drug Development	N/A	N/A	N/A
Mary-Ann Rennie	Head of Corporate Operations	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson's disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the advancement of Emyria's MDMA analogue drug development program, targeting mental health and neurodegenerative diseases, including Parkinson's. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.

Corporate governance

Emyria Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.